High-dose mitomycin C-containing regimens in the treatment of advanced gastric cancer
In 136 patients (115 males and 21 females) with advanced gastric cancer confirmed histologically, a regimen of high‐dose mitomycin C plus tegafur or UFT was administered. Dosage of agents used and schedules were as follows: MMC 20 mg i.v. once a week up to a total of 60 mg, followed either by tegafu...
Gespeichert in:
| Veröffentlicht in: | Seminars in surgical oncology 1994-03, Vol.10 (2), p.114-116 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 116 |
|---|---|
| container_issue | 2 |
| container_start_page | 114 |
| container_title | Seminars in surgical oncology |
| container_volume | 10 |
| creator | Jin, Maolin Yang, Boqin Zhang, Wei Wang, Yanmeng |
| description | In 136 patients (115 males and 21 females) with advanced gastric cancer confirmed histologically, a regimen of high‐dose mitomycin C plus tegafur or UFT was administered. Dosage of agents used and schedules were as follows: MMC 20 mg i.v. once a week up to a total of 60 mg, followed either by tegafur 600 mg/day p.o. to a total dosage of 20‐40 g, or by UFT 450 mg/day p.o., to a total dosage of 30 g. Patients' ages ranged from 24 to 75 years. Of this series, 70 patients were deemed inoperable, 21 patients underwent nonradical surgical operation, and the other 45 patients had postoperative recurrent disease. Of the 136 patients, 78 achieved complete tumour remission (CR) (21/136) and partial remission (PR) (57/136), yielding a response rate of 57.4%. The median duration of remission and survival was 5.2 (range 2‐16 + ) and 10.1 (range 3‐48 +) months. The main side effects were leukopenia and thrombocytopenia. None of these patients had liver or kidney function damage. © 1994 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/ssu.2980100210 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_ssu_2980100210</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SSU2980100210</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3780-af1deb23891d37aec3dc7818c77a95e9d2b7463f141ea55c319c13c67ec4ad9d3</originalsourceid><addsrcrecordid>eNqFkFFLwzAUhYMoc05ffRPyBzKTpm2SRxm6CUOFOZS9hCxJu-jajiRT9-_tqEx88uly7rnncPkAuCR4SDBOrkPYDhPB8V4QfAT6BAuOEsr5MehzluUIp5SdgrMQ3jAmJEtoD_Q4zhLGRB_MJ65cIdMECysXm2qnXQ1HSDd1VK52dQm9LV1l6wBbI64sjN6q2C4ibAqozIeqtTWwVCF6p6HeS38OTgq1DvbiZw7A_O72eTRB08fx_ehmijRlHCNVEGOX7a-CGMqU1dRoxgnXjCmRWWGSJUtzWpCUWJVlmhKhCdU5szpVRhg6AMOuV_smBG8LufGuUn4nCZZ7IrLFI3_xtIGrLrDZLitrDuc_PFpfdP6nW9vdP21yNpv_6UZd1oVovw5Z5d9lzijL5MvDWC5en8RikoykoN_XooGr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>High-dose mitomycin C-containing regimens in the treatment of advanced gastric cancer</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Jin, Maolin ; Yang, Boqin ; Zhang, Wei ; Wang, Yanmeng</creator><creatorcontrib>Jin, Maolin ; Yang, Boqin ; Zhang, Wei ; Wang, Yanmeng</creatorcontrib><description>In 136 patients (115 males and 21 females) with advanced gastric cancer confirmed histologically, a regimen of high‐dose mitomycin C plus tegafur or UFT was administered. Dosage of agents used and schedules were as follows: MMC 20 mg i.v. once a week up to a total of 60 mg, followed either by tegafur 600 mg/day p.o. to a total dosage of 20‐40 g, or by UFT 450 mg/day p.o., to a total dosage of 30 g. Patients' ages ranged from 24 to 75 years. Of this series, 70 patients were deemed inoperable, 21 patients underwent nonradical surgical operation, and the other 45 patients had postoperative recurrent disease. Of the 136 patients, 78 achieved complete tumour remission (CR) (21/136) and partial remission (PR) (57/136), yielding a response rate of 57.4%. The median duration of remission and survival was 5.2 (range 2‐16 + ) and 10.1 (range 3‐48 +) months. The main side effects were leukopenia and thrombocytopenia. None of these patients had liver or kidney function damage. © 1994 Wiley‐Liss, Inc.</description><identifier>ISSN: 8756-0437</identifier><identifier>EISSN: 1098-2388</identifier><identifier>DOI: 10.1002/ssu.2980100210</identifier><identifier>PMID: 8052779</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; chemotherapy ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Mitomycin - administration & dosage ; Mitomycin - adverse effects ; Stomach Neoplasms - drug therapy ; tegafur ; Tegafur - administration & dosage ; Treatment Outcome ; UFT</subject><ispartof>Seminars in surgical oncology, 1994-03, Vol.10 (2), p.114-116</ispartof><rights>Copyright © 1994 Wiley‐Liss, Inc., A Wiley Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3780-af1deb23891d37aec3dc7818c77a95e9d2b7463f141ea55c319c13c67ec4ad9d3</citedby><cites>FETCH-LOGICAL-c3780-af1deb23891d37aec3dc7818c77a95e9d2b7463f141ea55c319c13c67ec4ad9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fssu.2980100210$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fssu.2980100210$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8052779$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jin, Maolin</creatorcontrib><creatorcontrib>Yang, Boqin</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Wang, Yanmeng</creatorcontrib><title>High-dose mitomycin C-containing regimens in the treatment of advanced gastric cancer</title><title>Seminars in surgical oncology</title><addtitle>Semin. Surg. Oncol</addtitle><description>In 136 patients (115 males and 21 females) with advanced gastric cancer confirmed histologically, a regimen of high‐dose mitomycin C plus tegafur or UFT was administered. Dosage of agents used and schedules were as follows: MMC 20 mg i.v. once a week up to a total of 60 mg, followed either by tegafur 600 mg/day p.o. to a total dosage of 20‐40 g, or by UFT 450 mg/day p.o., to a total dosage of 30 g. Patients' ages ranged from 24 to 75 years. Of this series, 70 patients were deemed inoperable, 21 patients underwent nonradical surgical operation, and the other 45 patients had postoperative recurrent disease. Of the 136 patients, 78 achieved complete tumour remission (CR) (21/136) and partial remission (PR) (57/136), yielding a response rate of 57.4%. The median duration of remission and survival was 5.2 (range 2‐16 + ) and 10.1 (range 3‐48 +) months. The main side effects were leukopenia and thrombocytopenia. None of these patients had liver or kidney function damage. © 1994 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>chemotherapy</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mitomycin - administration & dosage</subject><subject>Mitomycin - adverse effects</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>tegafur</subject><subject>Tegafur - administration & dosage</subject><subject>Treatment Outcome</subject><subject>UFT</subject><issn>8756-0437</issn><issn>1098-2388</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkFFLwzAUhYMoc05ffRPyBzKTpm2SRxm6CUOFOZS9hCxJu-jajiRT9-_tqEx88uly7rnncPkAuCR4SDBOrkPYDhPB8V4QfAT6BAuOEsr5MehzluUIp5SdgrMQ3jAmJEtoD_Q4zhLGRB_MJ65cIdMECysXm2qnXQ1HSDd1VK52dQm9LV1l6wBbI64sjN6q2C4ibAqozIeqtTWwVCF6p6HeS38OTgq1DvbiZw7A_O72eTRB08fx_ehmijRlHCNVEGOX7a-CGMqU1dRoxgnXjCmRWWGSJUtzWpCUWJVlmhKhCdU5szpVRhg6AMOuV_smBG8LufGuUn4nCZZ7IrLFI3_xtIGrLrDZLitrDuc_PFpfdP6nW9vdP21yNpv_6UZd1oVovw5Z5d9lzijL5MvDWC5en8RikoykoN_XooGr</recordid><startdate>199403</startdate><enddate>199403</enddate><creator>Jin, Maolin</creator><creator>Yang, Boqin</creator><creator>Zhang, Wei</creator><creator>Wang, Yanmeng</creator><general>John Wiley & Sons, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199403</creationdate><title>High-dose mitomycin C-containing regimens in the treatment of advanced gastric cancer</title><author>Jin, Maolin ; Yang, Boqin ; Zhang, Wei ; Wang, Yanmeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3780-af1deb23891d37aec3dc7818c77a95e9d2b7463f141ea55c319c13c67ec4ad9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>chemotherapy</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mitomycin - administration & dosage</topic><topic>Mitomycin - adverse effects</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>tegafur</topic><topic>Tegafur - administration & dosage</topic><topic>Treatment Outcome</topic><topic>UFT</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jin, Maolin</creatorcontrib><creatorcontrib>Yang, Boqin</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Wang, Yanmeng</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Seminars in surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jin, Maolin</au><au>Yang, Boqin</au><au>Zhang, Wei</au><au>Wang, Yanmeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-dose mitomycin C-containing regimens in the treatment of advanced gastric cancer</atitle><jtitle>Seminars in surgical oncology</jtitle><addtitle>Semin. Surg. Oncol</addtitle><date>1994-03</date><risdate>1994</risdate><volume>10</volume><issue>2</issue><spage>114</spage><epage>116</epage><pages>114-116</pages><issn>8756-0437</issn><eissn>1098-2388</eissn><abstract>In 136 patients (115 males and 21 females) with advanced gastric cancer confirmed histologically, a regimen of high‐dose mitomycin C plus tegafur or UFT was administered. Dosage of agents used and schedules were as follows: MMC 20 mg i.v. once a week up to a total of 60 mg, followed either by tegafur 600 mg/day p.o. to a total dosage of 20‐40 g, or by UFT 450 mg/day p.o., to a total dosage of 30 g. Patients' ages ranged from 24 to 75 years. Of this series, 70 patients were deemed inoperable, 21 patients underwent nonradical surgical operation, and the other 45 patients had postoperative recurrent disease. Of the 136 patients, 78 achieved complete tumour remission (CR) (21/136) and partial remission (PR) (57/136), yielding a response rate of 57.4%. The median duration of remission and survival was 5.2 (range 2‐16 + ) and 10.1 (range 3‐48 +) months. The main side effects were leukopenia and thrombocytopenia. None of these patients had liver or kidney function damage. © 1994 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>8052779</pmid><doi>10.1002/ssu.2980100210</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8756-0437 |
| ispartof | Seminars in surgical oncology, 1994-03, Vol.10 (2), p.114-116 |
| issn | 8756-0437 1098-2388 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_ssu_2980100210 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects chemotherapy Drug Administration Schedule Female Humans Male Middle Aged Mitomycin - administration & dosage Mitomycin - adverse effects Stomach Neoplasms - drug therapy tegafur Tegafur - administration & dosage Treatment Outcome UFT |
| title | High-dose mitomycin C-containing regimens in the treatment of advanced gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A55%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-dose%20mitomycin%20C-containing%20regimens%20in%20the%20treatment%20of%20advanced%20gastric%20cancer&rft.jtitle=Seminars%20in%20surgical%20oncology&rft.au=Jin,%20Maolin&rft.date=1994-03&rft.volume=10&rft.issue=2&rft.spage=114&rft.epage=116&rft.pages=114-116&rft.issn=8756-0437&rft.eissn=1098-2388&rft_id=info:doi/10.1002/ssu.2980100210&rft_dat=%3Cwiley_cross%3ESSU2980100210%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8052779&rfr_iscdi=true |